Overview

Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency

Status:
COMPLETED
Trial end date:
2023-09-27
Target enrollment:
Participant gender:
Summary
To evaluate and compare the safety and efficacy of FCN-437c in subjects with mild and moderate liver impairment and healthy subjects, and to provide a basis for clinical medication in patients with liver impairment.
Phase:
PHASE1
Details
Lead Sponsor:
Ahon Pharmaceutical Co., Ltd.
Treatments:
FCN-437c